Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors

被引：2

作者：

Dasari, Srilatha ^{[1
]}

Tse, William ^{[2
]}

Wang, Jiasheng ^{[3
,4
]}

机构：

[1] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Internal Med, Cleveland, OH USA

[2] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Hematol & Oncol, Cleveland, OH USA

[3] Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Dept Hematol & Oncol, Cleveland, OH USA

[4] Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Dept Hematol & Oncol, 11100 Euclid Ave, Cleveland, OH 44106 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 202卷 / 06期

关键词：

aplastic anaemia; bone marrow failure; immune checkpoint inhibitors; immune-related adverse events; ADVERSE EVENTS; MANAGEMENT;

D O I：

10.1111/bjh.18985

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aplastic anaemia (AA) is a rare immune-related adverse events (irAEs) after immune checkpoint inhibitors (ICIs) administration with poorly understood incidence and outcomes. We analysed an electronic health record database of 52 303 ICI-treated patients and found 77 (0.15%) cases of AA, with a median onset of 126 days (interquartile range, 58-363 days). The most used treatment for AA was systemic glucocorticoids 60 (77.9%) and 32 (41.6%) patients were able to resume ICI within 1 year. Patients diagnosed with AA had a steep decline in overall survival (OS) within the first 120 days; when compared to propensity score-matched patients without AA, they had a significantly worse OS (hazard ratio 1.72, 95% confidence interval 1.19-2.50; p = 0.003).

引用

页码：1205 / 1208

页数：4

共 16 条

[1] Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors [J].

Chennamadhavuni, Adithya ;

Abushahin, Laith ;

Jin, Ning ;

Presley, Carolyn J. ;

Manne, Ashish .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[2] Hematologic Complications of Immune Checkpoint Inhibitors [J].

Davis, Elizabeth J. ;

Salem, Joe-Elie ;

Young, Arissa ;

Green, Jennifer R. ;

Ferrell, P. Brent ;

Ancell, Kristin K. ;

Lebrun-Vignes, Benedicte ;

Moslehi, Javid J. ;

Johnson, Douglas B. .

ONCOLOGIST, 2019, 24 (05) :584-588

[3]

Delaney N, 2019, LANCET HAEMATOL, V6, pE48, DOI [10.1016/52352-3026(18)30175-3, 10.1016/S2352-3026(18)30175-3]

[4] Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations [J].

Gong, Jun ;

Chehrazi-Raffle, Alexander ;

Reddi, Srikanth ;

Salgia, Ravi .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[5] Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma [J].

Helgadottir, H. ;

Kis, L. ;

Ljungman, P. ;

Larkin, J. ;

Kefford, R. ;

Ascierto, P. A. ;

Hansson, J. ;

Masucci, G. .

ANNALS OF ONCOLOGY, 2017, 28 (07) :1672-1673

[6] ICD-10 codes used to identify adverse drug events in administrative data: a systematic review [J].

Hohl, Corinne M. ;

Karpov, Andrei ;

Reddekopp, Lisa ;

Stausberg, Juergen .

JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (03) :547-557

[7] Hematologic complications of immune checkpoint inhibitors [J].

Kroll, Michael H. ;

Rojas-Hernandez, Cristhiam ;

Yee, Cassian .

BLOOD, 2022, 139 (25) :3594-3604

[8] Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database [J].

Martin, Mickael ;

Nguyen, Hoan-My ;

Beuvon, Clement ;

Bene, Johana ;

Palassin, Pascale ;

Atzenhoffer, Marina ;

Rouby, Franck ;

Sassier, Marion ;

Perault-Pochat, Marie-Christine ;

Roblot, Pascal ;

Allouchery, Marion ;

Puyade, Mathieu .

CANCERS, 2022, 14 (20)

[9] Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance [J].

Martins, Filipe ;

Sofiya, Latifyan ;

Sykiotis, Gerasimos P. ;

Lamine, Faiza ;

Maillard, Michel ;

Fraga, Montserrat ;

Shabafrouz, Keyvan ;

Ribi, Camillo ;

Cairoli, Anne ;

Guex-Crosier, Yan ;

Kuntzer, Thierry ;

Michielin, Olivier ;

Peters, Solange ;

Coukos, Georges ;

Spertini, Francois ;

Thompson, John A. ;

Obeid, Michel .

NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (09) :563-580

[10] Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report [J].

Meyers, D. E. ;

Hill, W. F. ;

Suo, A. ;

Jimenez-Zepeda, V. ;

Cheng, T. ;

Nixon, N. A. .

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7

← 1 2 →